We are thrilled to announce our investment in InterVenn Biosciences Aldo Carrascoso! Sarah Catanzaro shares more about the incredible founders & their differentiated approach to solving some of the most challenging problems in disease diagnosis with #AI, #massspec & #datascience. medium.com/amplify-partne…

Computational proteomics will transform diagnostic and therapeutic development. I'm so excited to back the InterVenn Biosciences as they pave the way in this exciting domain: medium.com/amplify-partne…

We are #live! bit.ly/2PzCzvc

Thanks Sarah Catanzaro and the Amplify Partners team!!!

InterVenn Biosciences raises $9.4 million from Genoa Ventures True Ventures Amplify Partners and others as the company aims to use #massspec, data science and #AI to find solutions to the biggest #health problems #cancer #cancerresearch #ovariancancer #fundingnews businesswire.com/news/home/2018…

@VennBio raises $9.4 million from Genoa Ventures True Ventures Amplify Partners and others as the company aims to use #massspec, data science and #AI to find solutions to the biggest #health problems #cancer #cancerresearch #ovariancancer #fundingnews businesswire.com/news/home/2018…

Today, we’re excited to add another healthcare company to the True portfolio with our investment in InterVenn Biosciences and its co-founders Aldo Carrascoso and Lieza Danan trueventures.com/intervenn-bios… cc Adam D'Augelli

Congratulations to Aldo Carrascoso and the entire InterVenn Biosciences team. Computation is reimagining what can be done in life sciences and you are at the forefront. Excited for when you show your breakthrough tech to the world!

Huge congrats to second time Boost VC founder Aldo Carrascoso on the fundraise and public announcement of InterVenn Biosciences! 🧬+💻 = 😍

Woohoo to InterVenn Biosciences! Hard problem, big impact. Keep saving the world. businesswire.com/news/home/2018…

Thanks Adam Draper ⏻ !! Great working with you and the rest of the Boost VC team!!

InterVenn Bio (InterVenn Biosciences): mass spec + glycoproteomics + AI = diagnostics. Genoa Ventures is thrilled to announce our newest portfolio company at the intersection of biology x technology!

Prediction: InterVenn Biosciences will be an important company that will be successful in early detection of disease. Congrats to @CarolynBertozzi !

Read #InterVenn cofounder Carlito Lebrilla's blog on the many roles of #Glycans in #Cancers intervenn.bio/blog/glycans-a… #glycoproteomics #ArtificialIntelligence

InterVenn Biosciences Announces Positive Interim Clinical Trial Results and Appoints Biotech Veteran Klaus Lindpaintner, M.D. as Chief Scientific and Medical Officer businesswire.com/news/home/2019…

Connect with us at J.P. Morgan 2020 Healthcare Conference #JPM2020 ! [email protected] #Sanfrancisco #endcancer #AI #intervenn #PrecisionMedicine

Happy New Year from #intervenn! Be sure to connect with us #JPM2020 intervenn.bio/events/ #endcancer #AI

Join us as Dr. Klaus Lindpainter (CSO/CMO) speaking at #PMWC20 Friday 24th 9am, Track 7 #endcancer #intervenn pmwcintl.com/speakers/

Make sure you check out our Booth B1005 @ #PMWC20 and book your exclusive 1:1 glycoprotein session via: calendly.com/intervenn/pmwc… #PMWC20 #endcancer #intervenn #networking #AI #PrecisionMedicine